QSQingxian Song

Qingxian Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingxian Song has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Shu Su

    Key Laboratory of Molecular Biology for Infectious Diseases, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    2 shared publications
  • Huiyi Zhang

    Key Laboratory of Molecular Biology for Infectious Diseases, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    1 shared publication
  • Jun Yuan

    Key Laboratory of Molecular Biology for Infectious Diseases, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    1 shared publication
  • Meng Jia

    Key Laboratory of Molecular Biology for Infectious Diseases, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China

    1 shared publication
  • Qianqian Shen

    Chongqing Yuzhong Center for Disease Control and Prevention

    1 shared publication
  • Tengxiao Long

    The Second Affiliated Hospital of Chongqing Medical University

    1 shared publication

Latest Publications

  • Towards patient-centered HIV drug resistance testing services in China: A discrete choice experiment

    by Qingxian Song, Qianqian Shen, Tengxiao Long, Yingni Yu, Shu Su

    Background: HIV drug resistance testing plays an important role in optimizing antiretroviral therapy, yet routine testing remains limited in China. This study applied a discrete choice experiment to evaluate patient preferences and willingness-to-pay for HIV drug resistance testing; to inform patient-centered implementation strategies for HIV drug resistance testing. Methods: Between April and June 2025, people living with HIV were recruited from community healthcare centers in China. Mixed logit models and latent class analysis were used to quantify attribute trade-offs, identify preference heterogeneity, and estimate willingness-to-pay across clinical and demographic subgroups. Results: Among 204 participants, out-of-pocket cost was the dominant barrier to uptake, accounting for 62.3% of overall decision importance. Testing after treatment failure ( β = 0.862), and doctor recommendation ( β = 0.519) were primary determinants of choice (all p < 0.001). Combined testing ( p = 0.037), shorter waiting time (3 days: p = 0.008), and high accuracy ( p = 0.031) also significantly increased testing preference. Latent class analysis identified two distinct subgroups. Class 1 (failure-driven) prioritized testing after treatment failure ( β = 3.547) but showed a negative preference for combined testing and high accuracy (all p < 0.05). Class 2 (service-oriented) strongly valued doctor recommendation and high accuracy (all p < 0.01). Older participants (≥50 years old) had a higher willingness-to-pay for doctor recommendation than the younger (240.2 vs 115.7 CNY), while younger showed higher WTP for combined testing and high accuracy. Conclusions: Reducing financial barriers, strengthening provider recommendations, and tailoring testing services to different patient preference patterns may improve HIV drug resistance testing uptake. These findings support patient-centered implementation strategies to promote earlier and more routine HIV drug resistance testing in China.

  • Open Access

    Dynamic AFP-Defined Disease State Transitions in Hospitalized Patients with Hepatocellular Carcinoma Using the Multi-State Markov Model: A Retrospective Cohort Study

    by Qingxian Song, Huiyi Zhang, Meng Jia, Yingni Yu, Ying Jiang, Jun Yuan, Shu Su

    Background: Hepatocellular carcinoma (HCC) exhibits highly variable disease trajectories, posing challenges for longitudinal monitoring and prognostic assessment. Alpha-fetoprotein (AFP) is widely used in HCC management, but transitions between discrete AFP states over time have not been explicitly modeled. Methods: We conducted a retrospective cohort study of 2,750 hospitalized HCC patients between 2016 and 2024, encompassing 17,076 hospitalizations. AFP measurements were categorized into four clinical relevant states (S1–S4, from low to high). A multi-state Markov (MSM) model was constructed to estimate transition probabilities, transition rates, and sojourn times, and to assess the effects of hepatitis B virus (HBV) infection, antiviral therapy, and major clinical covariates. Longitudinal AFP transitions were visualized using Sankey diagrams. Results: Among 2,750 hospitalized HCC patients, AFP-defined disease states S1 and S4 were relatively stable, whereas intermediate states S2 and S3 exhibited frequent bidirectional transitions. Tenofovir disoproxil fumarate (TDF) therapy was associated with S2→S1 AFP decrease (HR 1.350, 95% CI 1.065– 1.710). Elevated alanine aminotransferase (ALT) showed bidirectional effects (S1→S2: HR 1.310, 95% CI 1.011– 1.696; S3→S4: HR 1.517, 95% CI 1.130– 2.035; S2→S1: HR 1.493, 95% CI 1.191– 1.872; S3→S2: HR 1.685, 95% CI 1.295– 2.193; S4→S3: HR 1.527, 95% CI 1.153– 2.021), while elevated aspartate aminotransferase (AST), and total bilirubin (TBIL) were associated with lower likelihood of AFP decrease (AST S4→S3: HR 0.664, 95% CI 0.486– 0.908; TBIL S3→S2: HR 0.687, 95% CI 0.492– 0.958; S4→S3: HR 0.674, 95% CI 0.472– 0.965). Shorter sojourn times and higher hospitalization frequencies indicated clinical instability in intermediate disease states, suggesting a potentially modifiable window for clinical intervention. Conclusion: This study characterizes dynamic AFP-defined disease state transitions in hospitalized patients with HCC. Intermediate disease states represent unstable but potentially modifiable phases strongly influenced by antiviral therapy and liver function status. These findings support the value of longitudinal AFP monitoring beyond single time-point assessment and individualized clinical management.